US2021187017A1PendingUtilityA1

Composition and method for the prevention and treatment of obesity

Assignee: VECTOR VITALE IP LLCPriority: Dec 20, 2019Filed: Oct 6, 2020Published: Jun 24, 2021
Est. expiryDec 20, 2039(~13.4 yrs left)· nominal 20-yr term from priority
A61K 31/197A61K 9/0019A61K 9/0053A61K 33/30
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for reducing the weight of an overweight or obese subject comprising administering a therapeutically effective amount of a composition comprising 64Zn-enriched zinc. A method for preventing or reducing weight gain comprising administering an effective amount of a composition comprising 64Zn-enriched zinc.

Claims

exact text as granted — not AI-modified
1 . A method of preventing overweightness or obesity comprising administering to a subject in need thereof a prophylactically or therapeutically effective amount composition comprising a  64 Zn e  compound or a salt thereof, wherein the  64 Zn e  compound or a salt thereof is at least 80%  64 Zn e . 
     
     
         2 . The method of  claim 1 , wherein the composition further comprises a diluent or an excipient. 
     
     
         3 . The method of  claim 2 , wherein the diluent is deuterium-depleted water. 
     
     
         4 . The method of  claim 1 , wherein the  64 Zn e  compound or a salt thereof is at least 95%  64 Zn e . 
     
     
         5 . The method of  claim 1 , wherein the  64 Zn e  compound or a salt thereof is at least 99%  64 Zn e . 
     
     
         6 . The method of  claim 1 , wherein the composition contains between 0.05 mg and 110 mg of  64 Zn e . 
     
     
         7 . The method of  claim 6 , wherein the composition contains between 1 and 10 mg of  64 Zn e . 
     
     
         8 . The method of  claim 1 , wherein the  64 Zn e  compound or a salt thereof is at least 90%  64 Zn e  and the composition is an aqueous solution in which  64 Zn e  is present at a concentration of between 0.1 mg/ml and 10 mg/ml. 
     
     
         9 . The method of  claim 1 , wherein  64 Zn e  is in a form of salt selected from the group consisting of zinc aspartate with 2 aspartic acid molecules, zinc sulfate, and zinc citrate wherein the zinc aspartate has the structure 
       
         
           
           
               
               
           
         
       
     
     
         10 . The method of  claim 1 , wherein the composition is administered by injection. 
     
     
         11 . The method of  claim 1 , wherein the composition is administered orally. 
     
     
         12 . A method of treating overweightness or obesity comprising administering to a subject in need thereof a prophylactically or therapeutically effective amount composition comprising a  64 Zn e  compound or a salt thereof, wherein the  64 Zn e  compound or a salt thereof is at least 80%  64 Zn e , wherein  64 Zn e  is in a form of salt selected from the group consisting of zinc aspartate with 2 aspartic acid molecules, zinc sulfate, and zinc citrate, wherein the zinc aspartate has the structure

Join the waitlist — get patent alerts

Track US2021187017A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.